Mazor Robotics, an Israel-based spine technology manufacturer, has seen a large increase in sales after the FDA recently approved marketing of the Emerald spinal-implant system, according to a Bloomberg Businessweek report.
The stock has gained 31 percent over the past year, giving the company a market value of $59 million. The company plans on marketing the implants in the second half of 2011, according to the report.
Read the Bloomberg Businessweek report on Mazor Robotics.
Read other coverage on Mazor:
- Mazor's SpineAssist Clinical Study Shows 98% Accuracy in Implant Placement
- Mazor Receives FDA Approval for SpineAssist and C-InSight For Spine Surgery
The stock has gained 31 percent over the past year, giving the company a market value of $59 million. The company plans on marketing the implants in the second half of 2011, according to the report.
Read the Bloomberg Businessweek report on Mazor Robotics.
Read other coverage on Mazor:
- Mazor's SpineAssist Clinical Study Shows 98% Accuracy in Implant Placement
- Mazor Receives FDA Approval for SpineAssist and C-InSight For Spine Surgery